60 Degrees Pharmaceuticals Inc (SXTP)

$1.39 -0.07 (-4.79%)
Market Cap 3.96M
Revenue (ttm) 1.41M
Net Income (ttm) -7.37M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -522.70%
Debt to Equity Ratio 0.00
Volume 21,500
Avg Vol 1,449,170
Day's Range N/A - N/A
Shares Out 2.64M
Stochastic %K 11%
Beta 2.69
Analysts Sell
Price Target $14.10

Company Profile

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal and pneumocystis pneumoni...

Industry: Biotechnology
Sector: Healthcare
Phone: 202 327 5422
Address:
1025 Connecticut Avenue NW, Suite 1000, Washington, United States
uptrend2025
uptrend2025 May. 15 at 8:06 PM
$SXTP Expecting some news next week. Low float former runner. 👀
0 · Reply
JB3
JB3 May. 15 at 1:47 PM
$SXTP Thoughts on this from other? I know Tafenoquine is a super effective drug for malaria and babesia. The main catalyst for this stock appears to be the phase trials for babesia. Any concerns from others regarding the healthcare community not recognizing chronic babesiosis as a real thing? Even if trials goes well, and they will, I am concerned the the current CDC guidance on Babesia may still make it tough for tafenoquine to get covered by insurance. I also have direct experience that Babesia is a chronic infection, tick got me two years ago. Babesia is no joke but sadly the ERs and PCPs in the US 100% minimize Babesia as a chronic infection. They believe the body just clears the infection on its own after a few weeks.
0 · Reply
durocali
durocali May. 15 at 1:17 PM
$SXTP bright side (if any)... EPS loss per share was lower than current SP. will be interesting to see where stock goes btw now and next Q
0 · Reply
focafoca99
focafoca99 May. 15 at 1:13 PM
$SXTP logs a wider Q1 loss as revenue slips to $162K.
1 · Reply
resistancebreakers
resistancebreakers May. 12 at 7:21 PM
$SXTP testing new indicator
0 · Reply
uptrend2025
uptrend2025 May. 11 at 9:10 PM
$SXTP Loaded today. I am ready if it dips to the $130 s
0 · Reply
Argesch
Argesch May. 11 at 8:27 AM
$SXTP Yes.... I see it coming
0 · Reply
uptrend2025
uptrend2025 May. 8 at 9:52 PM
$SXTP beauty ready to be awakened. Runs hard when it pops. Nano float.
0 · Reply
uptrend2025
uptrend2025 May. 6 at 2:38 PM
$SXTP Hope to see you over $2 soon
0 · Reply
SuperGreenToday
SuperGreenToday May. 6 at 3:19 AM
$SXTP
0 · Reply
Latest News on SXTP
60 Degrees Pharmaceuticals Announces First Quarter 2026 Results

May 15, 2026, 8:42 AM EDT - 11 hours ago

60 Degrees Pharmaceuticals Announces First Quarter 2026 Results

60 Degrees Pharmaceuticals Transcript: Biotech Resurgence: Platforms and Pipelines of Today's Innovators

Apr 16, 2026, 10:00 AM EDT - 4 weeks ago

60 Degrees Pharmaceuticals Transcript: Biotech Resurgence: Platforms and Pipelines of Today's Innovators

60 Degrees Pharmaceuticals reports Arakoda availability on Runway Health website

2026-04-15T12:37:07.000Z - 4 weeks ago

60 Degrees Pharmaceuticals reports Arakoda availability on Runway Health website

60 Degrees Pharmaceuticals Announces 2025 Annual Results

Mar 31, 2026, 7:01 AM EDT - 6 weeks ago

60 Degrees Pharmaceuticals Announces 2025 Annual Results

60 Degrees submits NDIN to FDA for Australian Chestnut Extract

2026-03-18T12:12:35.000Z - 2 months ago

60 Degrees submits NDIN to FDA for Australian Chestnut Extract

60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract

Mar 18, 2026, 8:01 AM EDT - 2 months ago

60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract

60 Degrees reports all patients cured of babesiosis after tafenoquine treatment

2026-03-11T11:30:55.000Z - 2 months ago

60 Degrees reports all patients cured of babesiosis after tafenoquine treatment

60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial

Mar 11, 2026, 7:24 AM EDT - 2 months ago

60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial

60 Degrees expands access to Arakoda with GoodRx partnership

2026-02-02T13:21:06.000Z - 3 months ago

60 Degrees expands access to Arakoda with GoodRx partnership

GDRX

60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership

Feb 2, 2026, 8:01 AM EST - 3 months ago

60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership

60 Degrees Pharmaceuticals to exercise option in agreement with FSU

2026-01-28T13:11:59.000Z - 3 months ago

60 Degrees Pharmaceuticals to exercise option in agreement with FSU

60 Degrees Pharmaceuticals target adjusted to $24 at H.C. Wainwright after split

2026-01-27T16:30:17.000Z - 3 months ago

60 Degrees Pharmaceuticals target adjusted to $24 at H.C. Wainwright after split

Here’s Why 60 Degrees Pharmaceuticals Stock (SXTP) Rocketed Today

2026-01-22T14:15:44.000Z - 4 months ago

Here’s Why 60 Degrees Pharmaceuticals Stock (SXTP) Rocketed Today

60 Degrees Pharmaceuticals announces partnership with Runway Health

2026-01-22T13:27:13.000Z - 4 months ago

60 Degrees Pharmaceuticals announces partnership with Runway Health

60 Degrees Pharmaceuticals Inc trading halted, news pending

2026-01-17T00:50:18.000Z - 4 months ago

60 Degrees Pharmaceuticals Inc trading halted, news pending

60 Degrees Pharmaceuticals announces approval of 1-for-4 reverse stock split

2026-01-15T13:21:52.000Z - 4 months ago

60 Degrees Pharmaceuticals announces approval of 1-for-4 reverse stock split

60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio

Jan 15, 2026, 8:01 AM EST - 4 months ago

60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio

60 Degrees announces detection of babesia infection in 24% of patients in study

2025-12-29T13:10:58.000Z - 4 months ago

60 Degrees announces detection of babesia infection in 24% of patients in study

60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State

Dec 29, 2025, 8:01 AM EST - 4 months ago

60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State

60 Degrees Pharmaceuticals expanding Arakoda sales and marketing in 2026

2025-12-11T13:15:24.000Z - 5 months ago

60 Degrees Pharmaceuticals expanding Arakoda sales and marketing in 2026

60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026

Dec 11, 2025, 8:01 AM EST - 5 months ago

60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026

60 Degrees announces central site for B-FREE study open for patient enrollment

2025-11-21T13:15:10.000Z - 6 months ago

60 Degrees announces central site for B-FREE study open for patient enrollment

60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine

Nov 21, 2025, 8:01 AM EST - 6 months ago

60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine

60 Degrees Pharmaceuticals assumed with a Buy at H.C. Wainwright

2025-11-14T11:20:34.000Z - 6 months ago

60 Degrees Pharmaceuticals assumed with a Buy at H.C. Wainwright

60 Degrees Pharmaceuticals reports Q3 EPS (66c) vs. ($4.65) last year

2025-11-13T19:00:50.000Z - 6 months ago

60 Degrees Pharmaceuticals reports Q3 EPS (66c) vs. ($4.65) last year

60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results

Nov 13, 2025, 1:51 PM EST - 6 months ago

60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results

60 Degrees Pharmaceuticals Transcript: Investor Update

Oct 22, 2025, 4:15 PM EDT - 7 months ago

60 Degrees Pharmaceuticals Transcript: Investor Update

60 Degrees announces first patient completed regimen in babesiosis trial

2025-10-15T11:20:38.000Z - 7 months ago

60 Degrees announces first patient completed regimen in babesiosis trial

60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study

Oct 15, 2025, 7:14 AM EDT - 7 months ago

60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study

60 Degrees Pharmaceuticals unveils name of chronic babesiosis trial

2025-10-09T11:11:27.000Z - 7 months ago

60 Degrees Pharmaceuticals unveils name of chronic babesiosis trial

60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study

Oct 9, 2025, 7:04 AM EDT - 7 months ago

60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study

60 Degrees Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 3:30 PM EDT - 8 months ago

60 Degrees Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 8:02 AM EDT - 9 months ago

60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference

60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference

Aug 21, 2025, 8:31 AM EDT - 9 months ago

60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference

60 Degrees selects Icahn School of Medicine as central site for Phase II study

2025-08-19T13:00:20.000Z - 9 months ago

60 Degrees selects Icahn School of Medicine as central site for Phase II study

60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

Aug 19, 2025, 8:54 AM EDT - 9 months ago

60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results

Aug 13, 2025, 4:14 PM EDT - 9 months ago

60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results

60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public Offering

Jul 16, 2025, 4:01 PM EDT - 10 months ago

60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public Offering

60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering

Jul 15, 2025, 9:10 AM EDT - 10 months ago

60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering

60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 Billion

Jul 15, 2025, 7:01 AM EDT - 10 months ago

60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 Billion

60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle Format

Jun 4, 2025, 8:56 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle Format

Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals

Jun 3, 2025, 8:49 AM EDT - 1 year ago

Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Announces First Quarter 2025 Results

May 15, 2025, 4:31 PM EDT - 1 year ago

60 Degrees Pharmaceuticals Announces First Quarter 2025 Results

Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey

Apr 22, 2025, 8:44 AM EDT - 1 year ago

Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey

Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21

Apr 10, 2025, 8:31 AM EDT - 1 year ago

Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21

Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health

Apr 8, 2025, 8:31 AM EDT - 1 year ago

Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health

60 Degrees Pharmaceuticals and Fathom Holdings Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Feb 21, 2025, 9:00 AM EST - 1 year ago

60 Degrees Pharmaceuticals and Fathom Holdings Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

FTHM

60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split

Feb 20, 2025, 10:36 AM EST - 1 year ago

60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split

Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®

Feb 11, 2025, 12:59 PM EST - 1 year ago

Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®

60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 6, 2025, 2:07 PM EST - 1 year ago

60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 5, 2025, 9:22 AM EST - 1 year ago

60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 30, 2025, 2:20 PM EST - 1 year ago

60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

Jan 28, 2025, 8:01 AM EST - 1 year ago

60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis

Jan 8, 2025, 8:02 AM EST - 1 year ago

60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis

Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention

Dec 23, 2024, 8:57 AM EST - 1 year ago

Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention

60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women's Hospital

Dec 11, 2024, 8:56 AM EST - 1 year ago

60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women's Hospital

VSee Health and 60 Degrees Pharmaceuticals Interviews Aired on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Dec 2, 2024, 4:05 PM EST - 1 year ago

VSee Health and 60 Degrees Pharmaceuticals Interviews Aired on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

VSEE

60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Nov 22, 2024, 9:00 AM EST - 1 year ago

60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

CANF

60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results

Nov 14, 2024, 2:31 PM EST - 1 year ago

60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results

60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch

Oct 3, 2024, 9:02 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch

60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Sep 4, 2024, 8:00 AM EDT - 1 year ago

60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements

Aug 28, 2024, 2:48 PM EDT - 1 year ago

60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements

60 Degrees Pharmaceuticals Announces Second Quarter 2024 Results

Aug 14, 2024, 11:01 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Announces Second Quarter 2024 Results

60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb Study

Aug 12, 2024, 9:12 AM EDT - 1 year ago

60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb Study

60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split

Aug 6, 2024, 9:26 AM EDT - 1 year ago

60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split

60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade Support

Jul 25, 2024, 9:02 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade Support

60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis Study

Jul 19, 2024, 8:29 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis Study

60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment

Jul 9, 2024, 6:31 AM EDT - 2 years ago

60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment

First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind

Jun 27, 2024, 7:59 AM EDT - 2 years ago

First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind

Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind

May 30, 2024, 7:59 AM EDT - 2 years ago

Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind

60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study

May 20, 2024, 7:59 AM EDT - 2 years ago

60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study

uptrend2025
uptrend2025 May. 15 at 8:06 PM
$SXTP Expecting some news next week. Low float former runner. 👀
0 · Reply
JB3
JB3 May. 15 at 1:47 PM
$SXTP Thoughts on this from other? I know Tafenoquine is a super effective drug for malaria and babesia. The main catalyst for this stock appears to be the phase trials for babesia. Any concerns from others regarding the healthcare community not recognizing chronic babesiosis as a real thing? Even if trials goes well, and they will, I am concerned the the current CDC guidance on Babesia may still make it tough for tafenoquine to get covered by insurance. I also have direct experience that Babesia is a chronic infection, tick got me two years ago. Babesia is no joke but sadly the ERs and PCPs in the US 100% minimize Babesia as a chronic infection. They believe the body just clears the infection on its own after a few weeks.
0 · Reply
durocali
durocali May. 15 at 1:17 PM
$SXTP bright side (if any)... EPS loss per share was lower than current SP. will be interesting to see where stock goes btw now and next Q
0 · Reply
focafoca99
focafoca99 May. 15 at 1:13 PM
$SXTP logs a wider Q1 loss as revenue slips to $162K.
1 · Reply
resistancebreakers
resistancebreakers May. 12 at 7:21 PM
$SXTP testing new indicator
0 · Reply
uptrend2025
uptrend2025 May. 11 at 9:10 PM
$SXTP Loaded today. I am ready if it dips to the $130 s
0 · Reply
Argesch
Argesch May. 11 at 8:27 AM
$SXTP Yes.... I see it coming
0 · Reply
uptrend2025
uptrend2025 May. 8 at 9:52 PM
$SXTP beauty ready to be awakened. Runs hard when it pops. Nano float.
0 · Reply
uptrend2025
uptrend2025 May. 6 at 2:38 PM
$SXTP Hope to see you over $2 soon
0 · Reply
SuperGreenToday
SuperGreenToday May. 6 at 3:19 AM
$SXTP
0 · Reply
uptrend2025
uptrend2025 May. 5 at 10:55 PM
$SXTP 👀 This one pops out of nowhere
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser May. 4 at 11:30 PM
$SXTP RSI: 23.01, MACD: -0.1242 Vol: 0.16, MA20: 1.75, MA50: 2.03 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
uptrend2025
uptrend2025 Apr. 28 at 4:03 PM
$SXTP 👀
0 · Reply
Washingtonstate
Washingtonstate Apr. 28 at 9:35 AM
$SXTP
0 · Reply
uptrend2025
uptrend2025 Apr. 24 at 5:25 PM
$SXTP Getting more interesting if it goes down further 👀
0 · Reply
Washingtonstate
Washingtonstate Apr. 23 at 11:12 PM
$SXTP https://share.google/ErlOKnGnihxQrve4p
0 · Reply
uptrend2025
uptrend2025 Apr. 23 at 9:43 PM
$SXTP Starting to get interesting again. 👀
0 · Reply
Kastila
Kastila Apr. 18 at 1:55 AM
$SXTP I'm interested buying the warrants here, What is the exercise price after the reverse split?
0 · Reply
Washingtonstate
Washingtonstate Apr. 17 at 3:25 PM
$SXTP looks like a great buy !
1 · Reply
uptrend2025
uptrend2025 Apr. 16 at 7:23 PM
$SXTP Dump after news. Will recover.
0 · Reply
Muntu84
Muntu84 Apr. 15 at 6:48 PM
$SXTP Bulls i thought we would have a run today..wtf!
1 · Reply
Kastila
Kastila Apr. 15 at 2:00 PM
$SXTP $SXTPW
0 · Reply